[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Inclusion criteria

• ✓. Signed informed consent from the patient.
• ✓. Patients of either gender, aged ≥ 18 years.
• ✓. Patients with a histologically proven diagnosis of marginal zone lymphoma (MZL) according to the World Health Organization (WHO) classification of lymphoid neoplasms. Patients must have a biopsy-proven nodal, extranodal, or splenic MZL (at the time of enrolment, the CXCR4 expression status will be unknown).
• ✓. Treatment-naïve.
• ✓. Negative pregnancy test in women capable of child-bearing and their agreement to use highly effective contraception for 1 month after the last dose of \[68Ga\]Ga-PTF and \[18F\]FDG.
• ✓. For male patients whose partner is of child-bearing potential: The patient is willing to ensure that he and his partner use effective contraception for 1 month after the last dose of \[68Ga\]Ga-PTF and \[18F\]FDG.
• ✓. Acceptable organ function, as evidenced by the following laboratory data:
• ✓. No renal impairment: Estimated glomerular filtration rate (eGFR) \> 30 mL/min/1.73 m2or creatinine clearance \> 60 mL/min by the Cockcroft-Gault equation or equivalent

Exclusion criteria